INAB IN8BIO INC

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA.

Details for the ASH 2024 presentation are as follows:

 Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide
  
 Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center
 Abstract #: 4823
 Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
 Date and Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM PDT
  

The abstract will be available online and can be accessed via the conference websites at . Reprints of the poster will also be accessible on the page of IN8bio’s website following the presentations.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogenic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit .

Investors & Company Contacts:

Glenn Schulman, PharmD, MPH

203.494.7411

Patrick McCall

IN8bio, Inc.

646.933.5603

Media Contact:

Kimberly Ha

KKH Advisors

917.291.5744



EN
05/11/2024

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports Second Quarter 2025 Financial Results and Recent Busine...

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years.Received the Host Region USA East Abstract Award at ISCT 2025 for IN8bio’s DeltEx™ manufacturing platform.Presented preclinical data at ASGCT 2025 on INB-619, a novel gamma-delta T cell engager, and its ability to induce pan-gamma-delta T cell expansion and target CD19+ B c...

August 7, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Trea...

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recen...

June 9, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GB...

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving...

June 2, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T C...

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in pa...

May 14, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell ...

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- . (...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch